ReviewMolecular and cellular biochemistry2026
Decoding the gut microbiota-mitochondrial-inflammasome axis in cardiovascular disease.
Review in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The inter-disciplinary relationship between the gut microbiota, mitochondrial function, and inflammation activation represents a frontier in understanding Cardiovascular complications. This comprehensive review provides a framework of the signalling networks that link these three biological systems and their collective impact on cardiovascular disease. The gut microbiota is a diverse ecological community comprising bacterial phyla, including Firmicutes, Bacteroidetes, Proteobacteria, and Actinobacteria, which contribute to the functions of distal organs by producing bioactive metabolites. We systematically examined how microbial dysbiosis participates in inflammasome and mitochondrial-derived cardiovascular pathophysiology. This review also provides insight into various molecular pathways (TLR, PI3K/AKT, JAK/STAT, MAPK, TRPV, CREB, TXNIP, YAP, MyD88 and NLRP3) and therapeutic interventions targeting this axis, including gut microbiota modulation agents, mitochondrial-targeted antioxidants, and inflammasome inhibitors, offering mechanistic insights into their cardioprotective effects. Using current evidence and data from PubMed, Google Scholar, Web of Science, and ResearchGate, we provide a mechanistic understanding of the gut microbiota-mitochondria-inflammasome axis. This triad represents a critical target in cardiovascular health and warrants new diagnostic and therapeutic strategies.
Indexed as
Identifiers
41324864What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.